Annette Kopp-Schneider

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3262239/publications.pdf

Version: 2024-02-01

101543 102487 5,167 133 36 66 g-index citations h-index papers 137 137 137 7171 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict. Biostatistics, 2022, 23, 328-344.	1.5	4
2	Effects of radiofrequency electromagnetic fields (RF EMF) on cancer in laboratory animal studies: A protocol for a systematic review. Environment International, 2022, 161, 107106.	10.0	8
3	On the feasibility of pediatric dose-finding trials in small samples with information from a preceding trial in adults. Journal of Biopharmaceutical Statistics, 2022, 32, 652-670.	0.8	O
4	Spectral organ fingerprints for machine learning-based intraoperative tissue classification with hyperspectral imaging in a porcine model. Scientific Reports, 2022, 12, .	3.3	17
5	The Medical Segmentation Decathlon. Nature Communications, 2022, 13, .	12.8	252
6	Equilibrium radionuclide angiography: Intra- and inter-observer repeatability and reproducibility in the assessment of cardiac systolic and diastolic function. Journal of Nuclear Cardiology, 2021, 28, 1304-1314.	2.1	7
7	An R-shiny application to calculate optimal designs for single substance and interaction trials in dose response experiments. Toxicology Letters, 2021, 337, 18-27.	0.8	2
8	Comparative validation of multi-instance instrument segmentation in endoscopy: Results of the ROBUST-MIS 2019 challenge. Medical Image Analysis, 2021, 70, 101920.	11.6	41
9	Comments on "Incorporating historical twoâ€arm data in clinical trials with binary outcome: A practical approach†by Manuel Feißt, Johannes Krisam and Meinhard Kieser. Pharmaceutical Statistics, 2021, 20, 196-198.	1.3	0
10	Comparison of observation-based and model-based identification of alert concentrations from concentration–expression data. Bioinformatics, 2021, 37, 1990-1996.	4.1	7
11	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
12	Deep learning can predict lymph node status directly from histology in colorectal cancer. European Journal of Cancer, 2021, 157, 464-473.	2.8	32
13	Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control. Biometrical Journal, 2020, 62, 361-374.	1.0	56
14	Exploratory identification of predictive biomarkers in randomized trials with normal endpoints. Statistics in Medicine, 2020, 39, 923-939.	1.6	6
15	Modeling dose–response functions for combination treatments with log-logistic or Weibull functions. Archives of Toxicology, 2020, 94, 197-204.	4.2	4
16	99mTc-MAG3 Diuretic Renography: Intra- and Inter-Observer Repeatability in the Assessment of Renal Function. Diagnostics, 2020, 10, 709.	2.6	5
17	BIAS: Transparent reporting of biomedical image analysis challenges. Medical Image Analysis, 2020, 66, 101796.	11.6	59
18	The design heatmap: A simple visualization of â€optimality design problems. Biometrical Journal, 2020, 62, 2013-2031.	1.0	1

#	Article	IF	CITATIONS
19	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer, 2020, 20, 523.	2.6	24
20	A perivascular niche in the bone marrow hosts quiescent and proliferating tumorigenic colorectal cancer cells. International Journal of Cancer, 2020, 147, 519-531.	5.1	5
21	Drawing statistical conclusions from experiments with multiple quantitative measurements per subject. Radiotherapy and Oncology, 2020, 152, 30-33.	0.6	1
22	GOLD stage predicts thoracic aortic calcifications in patients with COPD. Experimental and Therapeutic Medicine, 2019, 17, 967-973.	1.8	2
23	Model-based estimation of lowest observed effect concentration from replicate experiments to identify potential biomarkers of in vitro neurotoxicity. Archives of Toxicology, 2019, 93, 2635-2644.	4.2	1
24	Spontaneous lymphoblastoid cell lines from patients with Epstein-Barr virus infection show highly variable proliferation characteristics that correlate with the expression levels of viral microRNAs. PLoS ONE, 2019, 14, e0222847.	2.5	5
25	Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms. JAMA - Journal of the American Medical Association, 2019, 321, 1686.	7.4	22
26	Quantitative dynamic ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. Haematologica, 2019, 104, e420-e423.	3.5	12
27	How to evaluate agreement between quantitative measurements. Radiotherapy and Oncology, 2019, 141, 321-326.	0.6	8
28	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Research, 2019, 29, 178-186.	1.2	43
29	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. Cancer Immunology, Immunotherapy, 2019, 68, 297-303.	4.2	45
30	Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach. Biometrical Journal, 2019, 61, 488-502.	1.0	4
31	Multipleâ€rater kappas for binary data: Models and interpretation. Biometrical Journal, 2018, 60, 381-394.	1.0	15
32	Exploiting the potential of unlabeled endoscopic video data with self-supervised learning. International Journal of Computer Assisted Radiology and Surgery, 2018, 13, 925-933.	2.8	93
33	Optimal experimental designs for estimating the drug combination index in toxicology. Computational Statistics and Data Analysis, 2018, 117, 182-193.	1.2	7
34	Prediction accuracy and variable selection for penalized causeâ€specific hazards models. Biometrical Journal, 2018, 60, 288-306.	1.0	7
35	Addressing small sample size bias in multipleâ€biomarker trials: Inclusion of biomarkerâ€negative patients and Firth correction. Biometrical Journal, 2018, 60, 275-287.	1.0	2
36	Persistence of Epigenomic Effects After Recovery From Repeated Treatment With Two Nephrocarcinogens. Frontiers in Genetics, 2018, 9, 558.	2.3	4

#	Article	IF	CITATIONS
37	Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases. Frontiers in Genetics, 2018, 9, 429.	2.3	21
38	Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Archives of Toxicology, 2018, 92, 1939-1952.	4.2	34
39	Parametric modeling and optimal experimental designs for estimating isobolograms for drug interactions in toxicology. Journal of Biopharmaceutical Statistics, 2018, 28, 763-777.	0.8	4
40	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunology, Immunotherapy, 2018, 67, 1261-1270.	4.2	22
41	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death and Disease, 2017, 8, e2635-e2635.	6.3	48
42	Heterogeneous treatment effects in stratified clinical trials with timeâ€ŧoâ€event endpoints. Biometrical Journal, 2017, 59, 511-530.	1.0	5
43	Functional analysis of high-content high-throughput imaging data. Journal of Applied Statistics, 2017, 44, 1903-1919.	1.3	1
44	Dissecting and modeling the emergent murine TEC compartment during ontogeny. European Journal of Immunology, 2017, 47, 1153-1159.	2.9	13
45	Clustering of samples and variables with mixed-type data. PLoS ONE, 2017, 12, e0188274.	2.5	42
46	The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers. Oncotarget, 2017, 8, 10238-10254.	1.8	60
47	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. Oncotarget, 2017, 8, 76029-76043.	1.8	7
48	New <i>in vitro</i> system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples. PeerJ, 2017, 5, e3030.	2.0	6
49	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	3.7	138
50	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 2016, 22, 278-287.	30.7	184
51	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. Oncotarget, 2016, 7, 66344-66359.	1.8	30
52	Optimal experimental designs for dose–response studies with continuous endpoints. Archives of Toxicology, 2015, 89, 2059-2068.	4.2	29
53	Quantitative in vitro to in vivo extrapolation of tissues toxicity. Toxicology in Vitro, 2015, 30, 203-216.	2.4	25
54	Functional Additive Mixed Models. Journal of Computational and Graphical Statistics, 2015, 24, 477-501.	1.7	147

#	Article	IF	Citations
55	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicology in Vitro, 2015, 30, 27-35.	2.4	10
56	Statistical strategies for averaging EC50 from multiple dose–response experiments. Archives of Toxicology, 2015, 89, 2119-2127.	4.2	9
57	Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing. Toxicology in Vitro, 2015, 30, 7-18.	2.4	30
58	Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study. Toxicology in Vitro, 2015, 30, 106-116.	2.4	46
59	<i>GRHL1</i> Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Research, 2014, 74, 2604-2616.	0.9	54
60	Summarizing EC50 estimates from multiple doseâ€response experiments: A comparison of a metaâ€analysis strategy to a mixedâ€effects model approach. Biometrical Journal, 2014, 56, 493-512.	1.0	27
61	Magnetic Resonance Imaging Detects Changes in Structure and Perfusion, and Response to Therapy in Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 956-965.	5.6	228
62	Stochastic timeâ€concentration activity models for cytotoxicity in 3D brain cell cultures. Theoretical Biology and Medical Modelling, 2013, 10, 19.	2.1	2
63	Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. International Journal of Cancer, 2013, 132, E139-48.	5.1	21
64	Design of a testing strategy using non-animal based test methods: Lessons learnt from the ACuteTox project. Toxicology in Vitro, 2013, 27, 1395-1401.	2.4	8
65	Validation of Fourier decomposition MRI with dynamic contrast-enhanced MRI using visual and automated scoring of pulmonary perfusion in young cystic fibrosis patients. European Journal of Radiology, 2013, 82, 2371-2377.	2.6	99
66	Data management in large-scale collaborative toxicity studies: How to file experimental data for automated statistical analysis. Toxicology in Vitro, 2013, 27, 1402-1409.	2.4	3
67	Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. Toxicology in Vitro, 2013, 27, 1416-1424.	2.4	41
68	Biological and Tumor-Promoting Effects of Dioxin-like and Non-Dioxin-like Polychlorinated Biphenyls in Mouse Liver After Single or Combined Treatment. Toxicological Sciences, 2013, 133, 29-41.	3.1	29
69	Transcriptomic Hepatotoxicity Signature of Chlorpromazine after Short- and Long-Term Exposure in Primary Human Sandwich Cultures. Drug Metabolism and Disposition, 2013, 41, 1835-1842.	3.3	31
70	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Research, 2013, 41, 6018-6033.	14.5	87
71	The role of perfusion effects in monitoring of chemoradiotherapy of rectal carcinoma using diffusion-weighted imaging. Cancer Imaging, 2013, 13, 548-556.	2.8	22
72	An Adaptive Group Sequential Phase II Design to Compare Treatments for Survival Endpoints in Rare Patient Entities. Journal of Biopharmaceutical Statistics, 2012, 22, 294-311.	0.8	3

#	Article	IF	Citations
7 3	The impact of data transformations on concentration–response modeling. Toxicology Letters, 2012, 213, 292-298.	0.8	24
74	Morphologic and functional scoring of cystic fibrosis lung disease using MRI. European Journal of Radiology, 2012, 81, 1321-1329.	2.6	163
7 5	Report of the EPAA–ECVAM Workshop on the Validation of Integrated Testing Strategies (ITS). ATLA Alternatives To Laboratory Animals, 2012, 40, 175-181.	1.0	24
76	Epstein-Barr Virus Stimulates Torque Teno Virus Replication: A Possible Relationship to Multiple Sclerosis. PLoS ONE, 2012, 7, e32160.	2.5	41
77	High-resolution phase-contrast MRI of aortic and pulmonary blood flow during rest and physical exercise using a MRI compatible bicycle ergometer. European Journal of Radiology, 2011, 80, 103-108.	2.6	23
78	The Feasibility of Low Mechanical Index Contrast Enhanced Ultrasound (CEUS) in Distinguishing Malignant from Benign Thoracic Lesions. Ultrasound in Medicine and Biology, 2011, 37, 1747-1754.	1.5	12
79	Concordance Analysis. Deutsches Ärzteblatt International, 2011, 108, 515-21.	0.9	117
80	Repeatability and Reproducibility of Quantitative Whole-lung Perfusion Magnetic Resonance Imaging. Journal of Thoracic Imaging, 2011, 26, 230-239.	1.5	23
81	E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice. PLoS Pathogens, 2011, 7, e1002125.	4.7	131
82	Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI. European Radiology, 2010, 20, 432-442.	4.5	73
83	Optimization and prevalidation of the in vitro ERα CALUX method to test estrogenic and antiestrogenic activity of compounds. Reproductive Toxicology, 2010, 30, 73-80.	2.9	74
84	Fine Tuning of the Threshold of T Cell Selection by the Nck Adapters. Journal of Immunology, 2010, 185, 7518-7526.	0.8	24
85	Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15529-15534.	7.1	30
86	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clinical Cancer Research, 2010, 16, 3240-3252.	7.0	175
87	Glossopharyngeal Insufflation and Pulmonary Hemodynamics in Elite Breath Hold Divers. Medicine and Science in Sports and Exercise, 2010, 42, 1688-1695.	0.4	19
88	Application of a two-phenotype color-shift model with heterogeneous growth to a rat hepatocarcinogenesis experiment. Mathematical Biosciences, 2010, 224, 95-100.	1.9	1
89	Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics. European Journal of Cancer, 2010, 46, 21-32.	2.8	11
90	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. Clinical Cancer Research, 2009, 15, 91-99.	7.0	335

#	Article	IF	CITATIONS
91	Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol \tilde{A}^3 gica, 2009, 48, 116-124.	1.8	89
92	Respiratory Displacement of the Thoracic Aorta: Physiological Phenomenon With Potential Implications for Thoracic Endovascular Repair. CardioVascular and Interventional Radiology, 2009, 32, 658-665.	2.0	14
93	Assessment of thoracic aortic conformational changes by four-dimensional computed tomography angiography in patients with chronic aortic dissection type b. European Radiology, 2009, 19, 245-253.	4.5	27
94	"ToxRToolâ€, a new tool to assess the reliability of toxicological data. Toxicology Letters, 2009, 189, 138-144.	0.8	271
95	Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy – A follow-up study. Radiotherapy and Oncology, 2009, 90, 408-412.	0.6	13
96	4D-CT-based target volume definition in stereotactic radiotherapy of lung tumours: Comparison with a conventional technique using individual margins. Radiotherapy and Oncology, 2009, 93, 419-423.	0.6	88
97	Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Letters, 2008, 264, 21-28.	7.2	27
98	Intrinsic Gating for Small-Animal Computed Tomography. Circulation: Cardiovascular Imaging, 2008, 1, 235-243.	2.6	34
99	Comparison of Mode of Action of Four Hepatocarcinogens: A Model-Based Approach. Toxicological Sciences, 2007, 99, 446-454.	3.1	18
100	Assessment of Morphological MRI for Pulmonary Changes in Cystic Fibrosis (CF) Patients. Investigative Radiology, 2007, 42, 715-724.	6.2	132
101	TTV infection in colorectal cancer tissues and normal mucosa. International Journal of Cancer, 2007, 121, 2109-2112.	5.1	23
102	Comparison of Software Tools to Improve the Detection of Carcinogen Induced Changes in the Rat Liver Proteome by Analyzing SELDI-TOFâ~MS Spectra. Journal of Proteome Research, 2006, 5, 254-261.	3.7	25
103	Investigating the Formation and Growth of α-Particle Radiation-Induced Foci of Altered Hepatocytes: A Model-Based Approach. Radiation Research, 2006, 166, 422-430.	1.5	8
104	Application of a color-shift model with heterogeneous growth to a rat hepatocarcinogenesis experiment. Mathematical Biosciences, 2006, 202, 248-268.	1.9	4
105	Stochastic Carcinogenesis Models. Wiley Series in Probability and Statistics, 2006, , 125-135.	0.0	1
106	Dose-Response Modeling. Wiley Series in Probability and Statistics, 2006, , 211-237.	0.0	4
107	Serological analysis of human renal cell carcinoma. International Journal of Cancer, 2006, 118, 2210-2219.	5.1	22
108	E6/E7 Expression of Human Papillomavirus Type 20 (HPV-20) and HPV-27 Influences Proliferation and Differentiation of the Skin in UV-Irradiated SKH-hr1 Transgenic Mice. Journal of Virology, 2006, 80, 11153-11164.	3.4	63

#	Article	IF	Citations
109	Differential signatures of protein expression in marmoset liver and thymus induced by single-dose TCDD treatment. Toxicology, 2005, 206, 33-48.	4.2	29
110	Reduced Expression of Interleukin-2 Decreases the Frequency of Alopecia Areata Onset in C3H/HeJ Mice. Journal of Investigative Dermatology, 2005, 125, 945-951.	0.7	21
111	Origins of the mutational origin of cancer. International Journal of Epidemiology, 2005, 34, 1168-1170.	1.9	8
112	Molecular approaches to the identification of biomarkers of exposure and effectâ€"report of an expert meeting organized by COST Action B15. Toxicology Letters, 2005, 156, 227-240.	0.8	26
113	Increased Incidence of Squamous Cell Carcinomas in Mastomys natalensis Papillomavirus E6 Transgenic Mice during Two-Stage Skin Carcinogenesis. Journal of Virology, 2004, 78, 4797-4805.	3.4	20
114	Biostatistical Evaluation of Focal Hepatic Preneoplasia. Toxicologic Pathology, 2003, 31, 121-125.	1.8	8
115	Biostatistical Evaluation of Focal Hepatic Preneoplasia. Toxicologic Pathology, 2003, 31, 121-125.	1.8	4
116	Prevalidation of a Rat Liver Foci Bioassay (RLFB) Based on Results from 1600 Rats: A Study Report. Toxicologic Pathology, 2003, 31, 60-79.	1.8	6
117	Incorporating phenotype-dependent growth rates into the color-shift model for preneoplastic hepatocellular lesions. Mathematical Biosciences, 2002, 179, 145-160.	1.9	5
118	Woodchuck hepatitis virus replication and antigen expression gradually decrease in preneoplastic hepatocellular lineages. Journal of Hepatology, 2002, 37, 478-485.	3.7	12
119	Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Mathematical Biosciences, 2001, 171, 113-142.	1.9	56
120	J-Shaped Dose-Response Relationship for Tumor Induction by Caffeic Acid in the Rat Forestomach, Modeled by Non-Monotonic Dose Response for DNA Damage and Cell Proliferation. Human and Ecological Risk Assessment (HERA), 2001, 7, 921-931.	3.4	4
121	Using a stochastic model to analyze the sequence of phenotypic changes in rat liver focal lesions. Mathematical and Computer Modelling, 2001, 33, 1289-1295.	2.0	1
122	A model for hepatocarcinogenesis with clonal expansion of three successive phenotypes of preneoplastic cells. Mathematical Biosciences, 2000, 168, 167-185.	1.9	10
123	Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks. Journal of Hepatology, 2000, 33, 580-600.	3.7	30
124	A model for hepatocarcinogenesis treating phenotypical changes in focal hepatocellular lesions as epigenetic events. Mathematical Biosciences, 1998, 148, 181-204.	1.9	26
125	Carcinogenesis models for risk assessment. Statistical Methods in Medical Research, 1997, 6, 317-340.	1.5	32
126	Calculating tumor incidence rates in stochastic models of carcinogenesis. Mathematical Biosciences, 1996, 135, 129-146.	1.9	35

#	Article	IF	CITATIONS
127	Carcinoma formation in NMRI mouse skin painting studies is a process suggesting greater than two stages. Carcinogenesis, 1995, 16, 53-59.	2.8	23
128	Porphyrin studies in TCDD-exposed workers. Archives of Toxicology, 1994, 68, 595-598.	4.2	11
129	Multistage Models of Carcinogenesis: An Approximation for the Size and Number Distribution of Late-Stage Clones. Risk Analysis, 1994, 14, 1039-1048.	2.7	14
130	The Exact Formula for Tumor Incidence in the Two-Stage Model. Risk Analysis, 1994, 14, 1079-1080.	2.7	60
131	A stem cell model for carcinogenesis. Mathematical Biosciences, 1994, 120, 211-232.	1.9	13
132	Birth and death/differentiation rates of papillomas in mouse skin. Carcinogenesis, 1992, 13, 973-978.	2.8	42
133	Birth—death processes with piecewise constant rates. Statistics and Probability Letters, 1992, 13, 121-127.	0.7	27